Amphista to initiate its first clinical trial for AMX-883, a potent, orally bioavailable DCAF16-dependent degrader of BRD9, for acute myeloid ...
The ASCERTAIN V clinical trial demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia ...
New research co-led by a Roswell Park Comprehensive Cancer Center leukemia expert highlights a promising investigational ...
Combining proteasome inhibitors with autophagy inhibitors disrupts acute myeloid leukemia (AML) cells' proteostasis, enhancing treatment efficacy and inducing programmed cell death. The novel therapy ...
By Dennis Thompson HealthDay ReporterFRIDAY, June 5, 2026 (HealthDay News) — An already available two-pill combo treats ...
Hosted on MSN
What To Know About Acute Myelogenous Leukemia (AML)
Acute myelogenous leukemia (AML), also known as acute myeloid leukemia, is a type of cancer that starts in your bone marrow (the soft, spongy tissue inside the bones that makes blood cells). AML is ...
Scientists from the German Cancer Research Center (DKFZ) and the HI-STEM* Stem Cell Institute have deciphered a key mechanism that contributes to treatment failure in acute myeloid leukemia (AML).
Acute myeloid leukemia (AML) is an aggressive blood cancer characterized by the accumulation of immature myeloid cells. Current treatments often fail to achieve durable remission, underscoring the ...
Even when patients with acute myeloid leukemia (AML) appear to be in remission, small numbers of cancer cells can remain in the body. These lingering cells—known as measurable residual disease ...
Measurable residual disease (MRD) assessment plays a critical role in monitoring acute myeloid leukemia (AML) progression and relapse risk. Current standard-of-care approaches, including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results